DexCom (NASDAQ:DXCM) Earns Buy Rating from Analysts at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of DexCom (NASDAQ:DXCM) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $85.00 target price on the medical device company’s stock.

Several other research firms have also commented on DXCM. Robert W. Baird dropped their target price on DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a report on Friday, September 26th. Piper Sandler increased their price target on DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Truist Financial lowered their price target on DexCom from $102.00 to $94.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a research report on Wednesday, October 8th. Finally, Citigroup lowered their price target on DexCom from $105.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $96.40.

DexCom Stock Up 0.5%

DexCom stock opened at $71.06 on Tuesday. The firm has a market cap of $27.87 billion, a price-to-earnings ratio of 49.35, a price-to-earnings-growth ratio of 1.49 and a beta of 1.47. DexCom has a 52 week low of $57.52 and a 52 week high of $93.25. The business’s 50-day moving average price is $72.59 and its 200 day moving average price is $77.71. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period last year, the company earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that DexCom will post 2.03 earnings per share for the current year.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 500 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the transaction, the executive vice president owned 94,102 shares in the company, valued at $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is owned by insiders.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of DexCom by 1.8% in the second quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock valued at $4,218,063,000 after acquiring an additional 866,506 shares in the last quarter. Jennison Associates LLC lifted its position in shares of DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after acquiring an additional 994,300 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of DexCom by 3.4% in the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after purchasing an additional 358,617 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after purchasing an additional 1,868,241 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of DexCom in the first quarter valued at approximately $554,893,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.